About Phenocell
Phenocell was founded in 2013 in Paris, France, and operates within the biotechnology sector. Cell-based assays for drug discovery are developed and supplied, with a focus on cellular models and bioassays for research purposes. The product range includes human iPSCs from various ethnicities, sebocytes, melanocytes, keratinocytes, and epithelial cells. Services encompass reprogramming and maintenance of cells.
- Headquarter Paris, France
- SectorsHealthcare
- Phone•••• ••••
- Website phenocell.com
- Social LinkedIn X Facebook
- Acquired by Axol Bioscience (Oct 2024)
- Latest Funding Round$415.68K (USD), Grant
Oct 2016
- InvestorsAxol Bioscience
& 1 more
- Acquired byAxol Bioscience
(Oct 2024)
Funding Insights of Phenocell
- Total Rounds 4
- Last Round Grant — $415,680
- First Round $526,417
(Jan 2015)
- Investors Count 1
All 4 funding rounds of Phenocell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | $415,680 | Grant | – | – | |
| Jan 2016 | $415,680 | Grant | – | – | |
| Nov 2015 | $526,417 | Grant | – | – | |
| Jan 2015 | $526,417 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Phenocell
Phenocell has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Axol Bioscience and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Human cells, reagents, and reprogramming services are supplied for research. | 2013 | axolbio.com | Cambridge, United Kingdom |
Investor details for Phenocell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Phenocell
4 dated milestones of Phenocell across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Phenocell is founded.
- Funding First funding round of $526K.
- Funding Latest funding round, Grant, of $416K.
- Exit Acquired by Axol Bioscience.
Similar companies to Phenocell
10 companies that operate in the same segment as Phenocell (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Phenocell
Phenocell was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Phenocell is headquartered in Paris, France.
Phenocell was founded in 2013 in Paris, France, and operates within the biotechnology sector. Cell-based assays for drug discovery are developed and supplied, with a focus on cellular models and bioassays for research purposes. The product range includes human iPSCs from various ethnicities, sebocytes, melanocytes, keratinocytes, and epithelial cells. Services encompass reprogramming and maintenance of cells.
Phenocell has 2 investors. Key investors include Axol Bioscience, and European Union.
Yes. Phenocell was acquired by Axol Bioscience in October 2024.